Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EO2463 |
| Synonyms | |
| Therapy Description |
EO2463 is a cancer vaccine comprised of microbiome-derived peptides homologous to tumor-associated antigens (TAA), which when presented by dendritic cells may lead to activation of T-cell mediated immune response against the TAAs expressed on tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EO2463 | EO 2463|EO-2463 | EO2463 is a cancer vaccine comprised of microbiome-derived peptides homologous to tumor-associated antigens (TAA), which when presented by dendritic cells may lead to activation of T-cell mediated immune response against the TAAs expressed on tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04669171 | Phase Ib/II | EO2463 EO2463 + Lenalidomide + Rituximab EO2463 + Rituximab | A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY) | Recruiting | USA | ITA | FRA | ESP | 0 |